Riociguat

Riociguat is a soluble guanylate cyclase (sGC) agonist with a pharmacological effect of vasodilation. It is commonly used clinically to improve the condition of chronic thromboembolic pulmonary hypertension (CTEPH) and arterial pulmonary hypertension (PAH).

CTEPH: Mainly used to treat postoperative persistent or recurrent CTEPH or inoperable CTEPH, and adult patients with World Health Organization cardiac function classification (WHO-FC) of II~III, can improve the patient’s exercise capacity.

PAH: Used alone or in combination with endothelin receptor antagonists or prostacyclins to treat adult patients with PAH and WHO-FC of II~III, thereby improving the patient’s exercise capacity.